Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
Top Cited Papers
Open Access
- 24 March 2021
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (10), 1306-1311
- https://doi.org/10.1136/annrheumdis-2021-220272
Abstract
Introduction In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become a high priority. Persons at risk of severe disease, for example, those receiving immunosuppressive therapies for chronic inflammatory cdiseases (CIDs), are prioritised for vaccination. However, data concerning generation of protective antibody titres in immunosuppressed patients are scarce. Additionally, mRNA vaccines represent a new vaccine technology leading to increased insecurity especially in patients with CID. Objective Here we present for the first time, data on the efficacy and safety of anti-SARS-CoV-2 mRNA vaccines in a cohort of immunosuppressed patients as compared with healthy controls. Methods 42 healthy controls and 26 patients with CID were included in this study (mean age 37.5 vs 50.5 years). Immunisations were performed according to national guidelines with mRNA vaccines. Antibody titres were assessed by ELISA before initial vaccination and 7 days after secondary vaccination. Disease activity and side effects were assessed prior to and 7 days after both vaccinations. Results Anti-SARS-CoV-2 antibodies as well as neutralising activity could be detected in all study participants. IgG titres were significantly lower in patients as compared with controls (2053 binding antibody units (BAU)/mL ±1218 vs 2685±1102). Side effects were comparable in both groups. No severe adverse effects were observed, and no patients experienced a disease flare. Conclusion We show that SARS-CoV-2 mRNA vaccines lead to development of antibodies in immunosuppressed patients without considerable side effects or induction of disease flares. Despite the small size of this cohort, we were able to demonstrate the efficiency and safety of mRNA vaccines in our cohort.Keywords
Funding Information
- BMBF (GAIN Network)
- DFG (Excellence Cluster "Precision Medicine in Chronic)
This publication has 23 references indexed in Scilit:
- Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International RegistryGastroenterology, 2020
- Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International MeetingGastroenterology, 2020
- Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximabAnnals Of The Rheumatic Diseases, 2020
- COVID-19 revisiting inflammatory pathways of arthritisNature Reviews Rheumatology, 2020
- Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registryAnnals Of The Rheumatic Diseases, 2020
- Aging and influenza vaccine-induced immunityCellular Immunology, 2019
- 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseasesAnnals Of The Rheumatic Diseases, 2019
- Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudyArthritis Research & Therapy, 2019
- Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2016
- Efficacy of a Hepatitis B Vaccination Schedule With Two Cycles of Four Double Doses of Conventional Vaccine and Four Doses of Adjuvanted Vaccine in Chronic Kidney Disease Patients Evaluated for Renal TransplantationTransplantation Proceedings, 2012